CBL and head and neck squamous cell carcinoma: Thus, we believe that we have identified an unexpected relationship between c-CBL and enhanced MET signaling in HNSCC and that c-CBL expression may therefore serve as a potential biomarker for the selection of patients that would benefit the most from MET inhibitor treatment.